The American Recovery and Reinvestment Act of 2009 provided $1.1 billion for comparative effectiveness research (CER). The Patient Protection and Affordable Care Act established the Patient-Centered ...
Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results